Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment

Ferlay, 2010, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008, Int J Cancer, 127, 2893, 10.1002/ijc.25516 Center, 2012, International variation in prostate cancer incidence and mortality rates, Eur Urol, 61, 1079, 10.1016/j.eururo.2012.02.054 Huggins, 1942, Effect of orchiectomy and irradiation on cancer of the prostate, Ann Surg, 115, 1192, 10.1097/00000658-194206000-00030 Mohler, 2008, Castration-recurrent prostate cancer is not androgen-independent, Adv Exp Med Biol, 617, 223, 10.1007/978-0-387-69080-3_21 Mohler, 2008, A role for the androgen-receptor in clinically localized and advanced prostate cancer, Best Pract Res Clin Endocrinol Metab, 22, 357, 10.1016/j.beem.2008.01.009 Azzouni, 2012, Biology of castration-recurrent prostate cancer, Urol Clin North Am, 39, 435, 10.1016/j.ucl.2012.07.002 Chen, 2009, Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target, Lancet Oncol, 10, 981, 10.1016/S1470-2045(09)70229-3 Potter, 1995, Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer, J Med Chem, 38, 2463, 10.1021/jm00013a022 Barrie, 1997, Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors, J Steroid Biochem Mol Biol, 60, 347, 10.1016/S0960-0760(96)00225-7 Jarman, 1998, The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors, J Med Chem, 41, 5375, 10.1021/jm981017j Attard, 2008, Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven, J Clin Oncol, 26, 4563, 10.1200/JCO.2007.15.9749 de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618 Ryan, 2011, Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response, Clin Cancer Res, 17, 4854, 10.1158/1078-0432.CCR-11-0815 Logothetis, 2012, Lancet Oncol, 13, 1210, 10.1016/S1470-2045(12)70473-4 Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096 Rathkopf, 2013, Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy [abstract 5], J Clin Oncol, 31 Taplin, 2012, Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): results of a randomized phase II study [abstract 4521], J Clin Oncol, 30 Kaku, 2011, Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer, Bioorg Med Chem, 19, 6383, 10.1016/j.bmc.2011.08.066 Hara, 2013, Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats, J Steroid Biochem Mol Biol, 134, 80, 10.1016/j.jsbmb.2012.10.020 Petrylak, 2013, J Clin Oncol, 31 Dreicer, 2012, J Clin Oncol, 30 Scher, 2010, Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study, Lancet, 375, 1437, 10.1016/S0140-6736(10)60172-9 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506 Baskin-Bey, 2012, TERRAIN: a randomized, double-blind, phase II study comparing MDV3100 with bicalutamide (Bic) in men with metastatic castrate-resistant prostate cancer (CRPC) [abstract TPS4698], J Clin Oncol, 30 Montgomery, 2012, A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer [abstract TPS4695], J Clin Oncol, 30 Clegg, 2012, ARN-509: a novel antiandrogen for prostate cancer treatment, Cancer Res, 72, 1494, 10.1158/0008-5472.CAN-11-3948 Rathkopf, 2012, A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC) [abstract TPS4697], J Clin Oncol, 30 Bruno, 2011, Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model, Steroids, 76, 1268, 10.1016/j.steroids.2011.06.002 Montgomery, 2012, Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC) [abstract 4665], J Clin Oncol, 30 Harris, 2011, A population-based study of prostate cancer chemotherapy, Clin Oncol, 23, 706, 10.1016/j.clon.2011.04.014 Tannock, 1996, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points, J Clin Oncol, 14, 1756, 10.1200/JCO.1996.14.6.1756 Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720 Petrylak, 2004, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, 351, 1513, 10.1056/NEJMoa041318 Chin, 2010, A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital, Curr Oncol, 17, 24, 10.3747/co.v17i2.482 Mita, 2009, Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors, Clin Cancer Res, 15, 723, 10.1158/1078-0432.CCR-08-0596 de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X De Bono, 2011, A subgr oup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) [abstract 4526], J Clin Oncol, 29 Ozguroglu, 2011, Impact of G-CSF prophylaxis on the occurrence of neutropenia in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel [abstract15131], J Clin Oncol, 29 Kantoff, 2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 411, 10.1056/NEJMoa1001294 Small, 2007, Granulocyte macrophage colony-stimulating factor—secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer, Clin Cancer Res, 13, 3883, 10.1158/1078-0432.CCR-06-2937 Higano, 2009, Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer, Cancer, 115, 3670, 10.1002/cncr.24429 DiPaola, 2006, A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer, J Transl Med, 4, 1, 10.1186/1479-5876-4-1 Kantoff, 2010, Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer, J Clin Oncol, 28, 1099, 10.1200/JCO.2009.25.0597 Slovin, 2013, Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study, Ann Oncol, 24, 1813, 10.1093/annonc/mdt107 Agata, 1996, Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes, Int Immunol, 8, 765, 10.1093/intimm/8.5.765 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, 366, 2455, 10.1056/NEJMoa1200694 Liepe, 2009, Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer, Curr Opin Investig Drugs, 10, 1346 Parker, 2012, Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract 8], J Clin Oncol, 30 Kelly, 2012, Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401, J Clin Oncol, 30, 1534, 10.1200/JCO.2011.39.4767 Petrylak, 2012, A phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients with castrate-resistant prostate cancer (CRPC): the MAINSAIL trial [abstract LBA24] Tannock, 2013, Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial, Lancet Oncol, 14, 760, 10.1016/S1470-2045(13)70184-0 Araujo, 2013, Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized phase III READY trial [abstract LBA8], J Clin Oncol, 31 Small, 2009, A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) [abstract 7], J Clin Oncol Scher, 2011, Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer, J Clin Oncol, 29, 2191, 10.1200/JCO.2010.32.8815 Quinn, 2012, SWOG S0421: phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC) [abstract 4511], J Clin Oncol, 30 Fizazi, 2013, Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer, J Clin Oncol, 31, 1740, 10.1200/JCO.2012.46.4149 Michaelson, 2011, Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC) [abstract 4515], J Clin Oncol, 29 Yakes, 2011, Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth, Mol Cancer Ther, 10, 2298, 10.1158/1535-7163.MCT-11-0264 Smith, 2013, Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial, J Clin Oncol, 31, 412, 10.1200/JCO.2012.45.0494 Armstrong, 2012, Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: results of long-term follow-up of a randomized phase II placebo-controlled trial [abstract 4550], J Clin Oncol, 30 Chi, 2010, Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer, J Clin Oncol, 28, 4247, 10.1200/JCO.2009.26.8771 Mezynski, 2012, Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?, Ann Oncol, 23, 2943, 10.1093/annonc/mds119 van Soest, 2013, Effects on androgen receptor nuclear import by docetaxel, cabazitaxel, abiraterone, and enzalutamide. Potential mechanisms for cross-resistance in castration-resistant prostate cancer (CRPC) [abstract 5064], J Clin Oncol, 31 Antonarakis, 2013, A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): immune results [abstract 5016], J Clin Oncol, 31 Mukherji, 2013, New treatment developments applied to elderly patients with advanced prostate cancer, Cancer Treat Rev, 39, 578, 10.1016/j.ctrv.2012.12.004 Malik, 2012, Post docetaxel treatment for castration-resistant prostate cancer (CRPC): does sequencing matter? [abstract e15135], J Clin Oncol, 30 Angelergues, 2013, Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: sequencing might matter [abstract 5063], J Clin Oncol, 31 Loriot, 2013, Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100), Ann Oncol, 24, 1807, 10.1093/annonc/mdt136 Noonan, 2013, Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide, Ann Oncol, 24, 1802, 10.1093/annonc/mdt138